(Q38187018)

30 August 2017

title

Asparaginase in the treatment of non-ALL hematologic malignancies (English)

1 reference

30 August 2017

Ashkan Emadi

1

1 reference

30 August 2017

Hania Zokaee

series ordinal

2

1 reference

30 August 2017

Edward A Sausville

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

11 February 2014

1 reference

Cancer Chemotherapy and Pharmacology

30 August 2017

published in

1 reference

30 August 2017

volume

73

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

875-883

1 reference

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Antagonism of purified asparaginase from guinea pig serum toward lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Structure of Helicobacter pylori L-asparaginase at 1.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-Asparaginase from the BCG Strain of Mycobacterium bovis. I. Purification and In Vitro Immunosuppressive Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

A Rapid Purification Procedure for L-Asparaginase from Vibrio Succinogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Structural characterization of Pseudomonas 7A glutaminase-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Antitumor enzyme: polyethylene glycol-modified asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Expanding targets for a metabolic therapy of cancer: L-asparaginase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Two L-asparaginases from E. coli and their action against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Childhood acute lymphoblastic leukaemia--current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparaginases: a successful class of drugs against leukemias and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Expression profiling after activation of amino acid deprivation response in HepG2 human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Therapy of acute leukemia with drug combinations which include asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

21 January 2018

Asparaginase revisited

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-Asparaginase and Human Malignant Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Cell-cycle inhibition by Helicobacter pylori L-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Helicobacter pyloril-asparaginase: a promising chemotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Diagnosis and management of natural killer-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Epidemiology of cancer-associated venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

A study on L-asparaginase of Nocardia levis MK-VL_113

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2402-3

10.1007/S00280-014-2402-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1040729931

0 references

1 reference